256 related articles for article (PubMed ID: 11121633)
1. Phase II, two-arm RTOG trial (94-11) of bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor volume (> 20 or < or = 20 cm(2), respectively) in the treatment of newly-diagnosed radiosurgery-ineligible glioblastoma multiforme patients.
Coughlin C; Scott C; Langer C; Coia L; Curran W; Rubin P
Int J Radiat Oncol Biol Phys; 2000 Dec; 48(5):1351-8. PubMed ID: 11121633
[TBL] [Abstract][Full Text] [Related]
2. Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group Study 83-02.
Werner-Wasik M; Scott CB; Nelson DF; Gaspar LE; Murray KJ; Fischbach JA; Nelson JS; Weinstein AS; Curran WJ
Cancer; 1996 Apr; 77(8):1535-43. PubMed ID: 8608540
[TBL] [Abstract][Full Text] [Related]
3. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.
Prados MD; Wara WM; Sneed PK; McDermott M; Chang SM; Rabbitt J; Page M; Malec M; Davis RL; Gutin PH; Lamborn K; Wilson CB; Phillips TL; Larson DA
Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):71-7. PubMed ID: 11163499
[TBL] [Abstract][Full Text] [Related]
4. NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients.
Ali AN; Zhang P; Yung WKA; Chen Y; Movsas B; Urtasun RC; Jones CU; Choi KN; Michalski JM; Fischbach AJ; Markoe AM; Schultz CJ; Penas-Prado M; Garg MK; Hartford AC; Kim HE; Won M; Curran WJ
J Neurooncol; 2018 Mar; 137(1):39-47. PubMed ID: 29404979
[TBL] [Abstract][Full Text] [Related]
5. Phase II radiation therapy oncology group trial of weekly paclitaxel and conventional external beam radiation therapy for supratentorial glioblastoma multiforme.
Langer CJ; Ruffer J; Rhodes H; Paulus R; Murray K; Movsas B; Curran W
Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):113-9. PubMed ID: 11516860
[TBL] [Abstract][Full Text] [Related]
6. Quality-adjusted survival analysis of malignant glioma. Patients treated with twice-daily radiation (RT) and carmustine: a report of Radiation Therapy Oncology Group (RTOG) 83-02.
Murray KJ; Nelson DF; Scott C; Fischbach AJ; Porter A; Farnan N; Curran WJ
Int J Radiat Oncol Biol Phys; 1995 Feb; 31(3):453-9. PubMed ID: 7852106
[TBL] [Abstract][Full Text] [Related]
7. Single-arm, open-label phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme.
Del Rowe J; Scott C; Werner-Wasik M; Bahary JP; Curran WJ; Urtasun RC; Fisher B
J Clin Oncol; 2000 Mar; 18(6):1254-9. PubMed ID: 10715295
[TBL] [Abstract][Full Text] [Related]
8. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol.
Souhami L; Seiferheld W; Brachman D; Podgorsak EB; Werner-Wasik M; Lustig R; Schultz CJ; Sause W; Okunieff P; Buckner J; Zamorano L; Mehta MP; Curran WJ
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):853-60. PubMed ID: 15465203
[TBL] [Abstract][Full Text] [Related]
9. Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials.
Buckner JC; Ballman KV; Michalak JC; Burton GV; Cascino TL; Schomberg PJ; Hawkins RB; Scheithauer BW; Sandler HM; Marks RS; O'Fallon JR; ;
J Clin Oncol; 2006 Aug; 24(24):3871-9. PubMed ID: 16921039
[TBL] [Abstract][Full Text] [Related]
10. Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial).
Mallick S; Kunhiparambath H; Gupta S; Benson R; Sharma S; Laviraj MA; Upadhyay AD; Julka PK; Sharma D; Rath GK
J Neurooncol; 2018 Oct; 140(1):75-82. PubMed ID: 29936695
[TBL] [Abstract][Full Text] [Related]
11. Hyperfractionated radiation therapy (HFX RT) followed by multiagent chemotherapy (CHT) in patients with malignant glioma: a phase II study.
Jeremic B; Grujicic D; Antunovic V; Djuric L; Stojanovic M; Shibamoto Y
Int J Radiat Oncol Biol Phys; 1994 Dec; 30(5):1179-85. PubMed ID: 7961028
[TBL] [Abstract][Full Text] [Related]
12. Concurrent accelerated hyperfractionated radiation therapy and carboplatin/etoposide in patients with malignant glioma: long-term results of a phase II study.
Jeremic B; Shibamoto Y; Grujicic D; Stojanovic M; Milicic B; Nikolic N; Dagovic A; Aleksandrovic J
J Neurooncol; 2001 Jan; 51(2):133-41. PubMed ID: 11386410
[TBL] [Abstract][Full Text] [Related]
13. Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis.
Panet-Raymond V; Souhami L; Roberge D; Kavan P; Shakibnia L; Muanza T; Lambert C; Leblanc R; Del Maestro R; Guiot MC; Shenouda G
Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):473-8. PubMed ID: 18554821
[TBL] [Abstract][Full Text] [Related]
14. Survival following CyberKnife radiosurgery and hypofractionated radiotherapy for newly diagnosed glioblastoma multiforme.
Lipani JD; Jackson PS; Soltys SG; Sato K; Adler JR
Technol Cancer Res Treat; 2008 Jun; 7(3):249-55. PubMed ID: 18473497
[TBL] [Abstract][Full Text] [Related]
15. A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: a report of the Radiation Therapy Oncology Group (RTOG) 9104.
Murray KJ; Scott C; Greenberg HM; Emami B; Seider M; Vora NL; Olson C; Whitton A; Movsas B; Curran W
Int J Radiat Oncol Biol Phys; 1997 Oct; 39(3):571-4. PubMed ID: 9336134
[TBL] [Abstract][Full Text] [Related]
16. A phase I dose-escalation study (ISIDE-BT-1) of accelerated IMRT with temozolomide in patients with glioblastoma.
Morganti AG; Balducci M; Salvati M; Esposito V; Romanelli P; Ferro M; Calista F; Digesù C; Macchia G; Ianiri M; Deodato F; Cilla S; Piermattei A; Valentini V; Cellini N; Cantore GP
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):92-7. PubMed ID: 19683876
[TBL] [Abstract][Full Text] [Related]
17. Phase I three-dimensional conformal radiation dose escalation study in newly diagnosed glioblastoma: Radiation Therapy Oncology Group Trial 98-03.
Tsien C; Moughan J; Michalski JM; Gilbert MR; Purdy J; Simpson J; Kresel JJ; Curran WJ; Diaz A; Mehta MP;
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):699-708. PubMed ID: 18723297
[TBL] [Abstract][Full Text] [Related]
18. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
[TBL] [Abstract][Full Text] [Related]
19. Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma--possible advantage observed at 72.0 Gy in 1.2 Gy B.I.D. fractions: report of the Radiation Therapy Oncology Group Protocol 8302.
Nelson DF; Curran WJ; Scott C; Nelson JS; Weinstein AS; Ahmad K; Constine LS; Murray K; Powlis WD; Mohiuddin M
Int J Radiat Oncol Biol Phys; 1993 Jan; 25(2):193-207. PubMed ID: 8380567
[TBL] [Abstract][Full Text] [Related]
20. Does stereotactic eligibility for the treatment of glioblastoma cause selection bias in randomized studies?
Lustig RA; Scott CB; Curran WJ
Am J Clin Oncol; 2004 Oct; 27(5):516-21. PubMed ID: 15596923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
